Todd E Fox
Overview
Explore the profile of Todd E Fox including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal I, Illendula A, Joyner A, Manavalan J, Deddens T, Sabzevari A, et al.
bioRxiv
. 2024 Jul;
PMID: 39071370
Histone deacetylase (HDAC) inhibitors are a widely recognized and valued treatment option for patients with relapsed or refractory peripheral T cell lymphomas (PTCL). Romidepsin is a relatively selective Class I...
2.
Ohya Y, Ogiso Y, Matsuda M, Sakae H, Nishida K, Miki Y, et al.
Cells
. 2024 Mar;
13(5.
PMID: 38474369
Regulated necrosis, termed necroptosis, represents a potential therapeutic target for refractory cancer. Ceramide nanoliposomes (CNLs), considered potential chemotherapeutic agents, induce necroptosis by targeting the activating protein mixed lineage kinase domain-like...
3.
Paudel B, Tan S, Fox T, Ung J, Golla U, Shaw J, et al.
Blood Adv
. 2024 Jan;
8(5):1137-1142.
PMID: 38170742
No abstract available.
4.
Ung J, Tan S, Fox T, Shaw J, Taori M, Horton B, et al.
Cancers (Basel)
. 2023 Dec;
15(24.
PMID: 38136410
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously...
5.
Ung J, Tan S, Fox T, Shaw J, Taori M, Horton B, et al.
bioRxiv
. 2023 Nov;
PMID: 37961314
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell death-promoting signaling lipid that plays a central role in therapy-induced cell death. Acid...
6.
Ciner A, Gourdin T, Davidson J, Parette M, Walker S, Fox T, et al.
Cancer Chemother Pharmacol
. 2023 Sep;
93(1):23-29.
PMID: 37736793
Purpose: Ceramide is a sphingolipid metabolite that deactivates multiple oncogenic signaling pathways and promotes cell death. In-vivo data demonstrate single-agent anti-cancer activity and enhanced efficacy with combination strategies. This phase...
7.
Feng T, Melchor S, Zhao X, Ghumman H, Kester M, Fox T, et al.
Heliyon
. 2023 Jul;
9(7):e17411.
PMID: 37456044
Cachexia is a life-threatening disease characterized by chronic, inflammatory muscle wasting and systemic metabolic impairment. Despite its high prevalence, there are no efficacious therapies for cachexia. Mice chronically infected with...
8.
Paudel B, Tan S, Fox T, Ung J, Shaw J, Dunton W, et al.
bioRxiv
. 2023 May;
PMID: 37131653
Acute myeloid leukemia (AML) is an aggressive disease with complex and heterogeneous biology. Although several genomic classifications have been proposed, there is a growing interest in going beyond genomics to...
9.
Fisher-Wellman K, Kassai M, Hagen J, Neufer P, Kester M, Loughran Jr T, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980769
Acute myelogenous leukemia (AML), the most prevalent acute and aggressive leukemia diagnosed in adults, often recurs as a difficult-to-treat, chemotherapy-resistant disease. Because chemotherapy resistance is a major obstacle to successful...
10.
Sakae H, Ogiso Y, Matsuda M, Shimora H, Deering T, Fox T, et al.
Cells
. 2023 Feb;
12(4).
PMID: 36831258
Ceramides are an emerging class of anti-inflammatory lipids, and nanoscale ceramide-delivery systems are potential therapeutic strategies for inflammatory diseases. This study investigated the therapeutic effects of ceramide nanoliposomes (CNL) on...